Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod.
Epidermodysplasia verruciformis (EV) is a rare disorder characterized by widespread human papillomavirus infection and malignant transformation. EV may be caused by mutations of the genes EVER1 or EVER2, which are located on the EV1 locus, 17q25. We describe a patient with EV and a novel homozygous gene mutation of EVER2 gene who was treated successfully with topical imiquimod.
Berthelot
Cindy
C
Medical School, University of Texas Southwestern Medical Center at Dallas, USA.
Dickerson
Mary C
MC
Rady
Peter
P
He
Qin
Q
Niroomand
Farhad
F
Tyring
Stephen K
SK
Pandya
Amit G
AG
D000287:Administration, Topical; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002280:Basal Cell Carcinoma / Q000209:etiology / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000209:etiology / Q000473:pathology / Q000628:therapy; D004819:Epidermodysplasia Verruciformis / Q000150:complications / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D000077271:Imiquimod; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D009154:Mutation; D012878:Skin Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D008565:Membrane Proteins; C470315:TMC8 protein, human; D000077271:Imiquimod